The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
By Eurasianet Central Asian labour migrants in Russia have long been subjected to harassment and abuse at the hands of ...
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025Full ...
EQS-News: ABIVAX / Key word (s): Annual Results Abivax Announces Full Year 2024 Financial Results 24.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.